2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Atherosclerosis D050197 85 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Endometriosis D004715 29 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Tsikas D et al. Solid- and liquid-phase extraction for the gas chromatographic-tandem mass spectrometric quantification of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-oxo-prostaglandin F1 alpha in human urine. 2000 J Chromatogr A pmid:10941682
Arnaud J et al. Effect of low dose antioxidant vitamin and trace element supplementation on the urinary concentrations of thromboxane and prostacyclin metabolites. 2007 J Am Coll Nutr pmid:17914127
Martineau A et al. Defective synthesis of vasodilator prostaglandins in the spontaneously hypertensive rat. 1984 Mar-Apr Hypertension pmid:6373595
Falardeau P and Martineau A In vivo production of prostaglandin I2 in Dahl salt-sensitive and salt-resistant rats. 1983 Sep-Oct Hypertension pmid:6352480
Minuz P et al. Altered excretion of prostaglandin and thromboxane metabolites in pregnancy-induced hypertension. 1988 Hypertension pmid:3290103
Guarner F et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. 1986 Gastroenterology pmid:3510938
Guarner C et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. 1992 Gastroenterology pmid:1727763
Watson ML et al. Systemic synthesis of prostaglandin I2 following sustained infusion of angiotensin II in conscious dogs. 1986 Eur. J. Pharmacol. pmid:3530786
Greer IA et al. Synergistic inhibitory effects of adrenoceptor antagonists and prostacyclin, and umbilical artery-derived prostacyclin-like activity on platelet aggregation. 1990 May-Jun Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:1970789
Larsson PT et al. Metoprolol does not reduce platelet aggregability during sympatho-adrenal stimulation. 1992 Eur. J. Clin. Pharmacol. pmid:1387607